WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013044816) CRYSTALLINE FORMS OF AZILSARTAN AND PREPARATION AND USES THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/044816    International Application No.:    PCT/CN2012/082106
Publication Date: 04.04.2013 International Filing Date: 27.09.2012
IPC:
C07D 413/10 (2006.01), A61K 31/4245 (2006.01), A61P 9/12 (2006.01)
Applicants: SUNSHINE LAKE PHARMA CO., LTD. [CN/CN]; Northern Industrial Area Songshan Lake Dongguan, Guangdong 523000 (CN).
RUYUAN HEC PHARM CO., LTD. [CN/CN]; Ruchengtown Ruyuan Yao Autonomous Cornty Guangdong 512721 (CN)
Inventors: LEI, Xin; (CN).
PENG, Jinan; (CN).
WANG, Tianming; (CN).
LV, Zhiqing; (CN).
LI, Wan; (CN)
Agent: CCPIT PATENT AND TRADEMARK LAW OFFICE; 8th Floor, Vantone New World Plaza 2 Fuchengmenwai Street, Xicheng District Beijing 100037 (CN)
Priority Data:
201110304249.8 30.09.2011 CN
201210013952.8 17.01.2012 CN
Title (EN) CRYSTALLINE FORMS OF AZILSARTAN AND PREPARATION AND USES THEREOF
(FR) FORMES CRISTALLINE D'AZILSARTAN ET LEUR PRÉPARATION ET LEURS UTILISATIONS
Abstract: front page image
(EN)The present invention relates to the field of pharmaceutical chemistry. Disclosed herein is a crystalline form of azilsartan, which is substantially pure. The crystalline form is crystalline form A, form B, form C, form D, form E, form F, form G, form H, form I, form J or form K. The substantially pure crystalline forms of azilsartan of the invention generally have good properties such as high solubility, high bioavailability, good stability, long shelf life and good antistatic property. The crystalline forms of azilsartan generally exhibit an excellent performance in reducing clinical systolic blood pressure (SBP) and average 24-hour SBP. Disclosed herein are methods of preparing the substantially pure crystalline forms of azilsartan, pharmaceutical compositions comprising the crystalline forms, and preparation methods and uses thereof.
(FR)La présente invention concerne le domaine de la chimie pharmaceutique. L'invention concerne une forme cristalline d'azilsartan, qui est essentiellement pure. La forme cristalline est la forme cristalline A, B, C, D, E, F, G, H, I, J ou K. Les formes cristallines essentiellement pures d'azilsartan de l'invention présentent généralement de bonnes propriétés telles qu'une grande solubilité, une grande biodisponibilité, une bonne stabilité, une durée de conservation longue et de bonnes propriétés antistatiques. Les formes cristallines d'azilsartan présentent généralement d'excellentes performances de réduction de la pression systolique (SBP) clinique et de la SBP moyenne sur 24 heures. L'invention concerne des procédés de préparation des formes cristallines essentiellement pures d'azilsartan, des compositions pharmaceutiques comprenant les formes cristallines, et leurs procédés de préparation et leurs utilisations.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)